Chimerix, Inc. (NASDAQ:CMRX) Shares Purchased by Pictet Asset Management SA

Pictet Asset Management SA boosted its position in Chimerix, Inc. (NASDAQ:CMRXGet Rating) by 109.6% in the second quarter, Holdings Channel.com reports. The firm owned 662,104 shares of the biopharmaceutical company’s stock after acquiring an additional 346,224 shares during the quarter. Pictet Asset Management SA’s holdings in Chimerix were worth $1,377,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Walleye Capital LLC acquired a new stake in Chimerix in the second quarter valued at about $863,000. Walleye Trading LLC purchased a new position in Chimerix in the second quarter valued at about $45,000. Monaco Asset Management SAM purchased a new position in Chimerix in the second quarter valued at about $3,077,000. SG Americas Securities LLC purchased a new position in Chimerix in the second quarter valued at about $30,000. Finally, Russell Investments Group Ltd. increased its holdings in Chimerix by 52.8% in the second quarter. Russell Investments Group Ltd. now owns 141,932 shares of the biopharmaceutical company’s stock valued at $294,000 after buying an additional 49,034 shares in the last quarter. Institutional investors and hedge funds own 63.43% of the company’s stock.

Insider Transactions at Chimerix

In other news, Director Fred A. Middleton bought 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 29th. The shares were purchased at an average price of $1.86 per share, for a total transaction of $37,200.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at $74,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.20% of the company’s stock.

Wall Street Analyst Weigh In

CMRX has been the subject of a number of research analyst reports. Capital One Financial initiated coverage on shares of Chimerix in a report on Wednesday, September 7th. They issued an “overweight” rating and a $7.00 target price for the company. StockNews.com raised shares of Chimerix from a “hold” rating to a “buy” rating in a report on Friday, November 4th. Four equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Chimerix presently has an average rating of “Buy” and a consensus price target of $8.50.

Chimerix Price Performance

Shares of CMRX opened at $2.21 on Wednesday. The firm has a 50 day simple moving average of $1.92 and a 200-day simple moving average of $2.12. Chimerix, Inc. has a 1-year low of $1.27 and a 1-year high of $7.42. The stock has a market cap of $194.58 million, a price-to-earnings ratio of 1.26 and a beta of 1.08.

About Chimerix

(Get Rating)

Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.

Featured Articles

Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix, Inc. (NASDAQ:CMRXGet Rating).

Institutional Ownership by Quarter for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.